Clinical trial OLYMPIA D081CC00006 BIG 6-13, NSABP B-55
A randomised, double-blind, parallel group, placebo-controlled multicentre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy (OLYMPIA study)
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | AstraZeneca |
| EudraCT Identifier | 2013-003839-30 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02032823 |
| Inclusion criteria | adjuvant TNBC |
| Last update |